Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Schizophrenia

para>All antipsychotics are associated with weight gain and carry the risk of metabolic SE and tardive dyskinesia. ‚  
  • Managing adverse effects of antipsychotics
    • Dystonic reaction (especially of head and neck): Give diphenhydramine 25 to 50 mg IM or benztropine 1 to 2 mg IM.
    • Akathisia: propranolol 10 mg BID or lorazepam 0.5 mg BID
    • Pseudoparkinsonism: trihexyphenidyl 2 mg BID (may be increased to 15 mg/day if needed) or benztropine 0.5 BID (range 1 to 4 mg/day)
    • Akathisia (restlessness): propranolol (30 to 60 mg in divided doses) or lorazepam (range 1 to 2 mg/day)
    • Neuroleptic malignant syndrome: hyperthermia, autonomic dysfunction, and extrapyramidal symptoms; requires hospitalization and supportive management (IVF and cessation of offending neuroleptic)
  • Geriatric considerations: All antipsychotics carry a black box warning for increased mortality risk in elderly dementia patients.
  • Adjunctive treatments
    • Benzodiazepines
      • May be effective adjuncts to antipsychotics during acute phase of illness
      • Useful for the treatment of catatonia
      • Withdrawal reactions with psychosis or seizures
    • Mood stabilizers (valproic acid lithium, lamotrigine, carbamazepine): may be effective adjuncts for those with agitated/violent behavior (7,9)[A]
    • Antidepressants: if prominent symptoms of depression are present
    • Metformin: helps minimize risk of metabolic SE with use of AP (10)[A]

ISSUES FOR REFERRAL


  • Consider in cases of suicidality, coexistence of an addiction, difficulty in engagement, or poor self-care.
  • Patients with schizophrenia should receive multidisciplinary care from both a primary care physician and a psychiatrist.
  • Family members often benefit from referral to family advocacy organizations such as NAMI (11)[A].

ADDITIONAL THERAPIES


Family and patient education and psychotherapy. These include specific treatments to reduce the impact of psychotic symptoms and to enhance social functioning. Cognitive-behavioral therapy has been shown to be effective for specific symptoms of schizophrenia (12)[C]. ‚  

COMPLEMENTARY & ALTERNATIVE MEDICINE


No alternative therapies are validated. ‚  

SURGERY/OTHER PROCEDURES


  • Electroconvulsive therapy (ECT): For patients presenting with catatonic features, the option of ECT should be considered early when insufficient response to benzodiazepines is observed (7)[B].
  • Surgical interventions are not available.

INPATIENT CONSIDERATIONS


Initial stabilization focuses on maintaining a safe environment and reducing acute psychotic symptoms and agitation through the initiation of pharmacologic treatment. ‚  
Admission Criteria/Initial Stabilization
The decision to admit is usually based on the patient 's risk of self-harm or harm to others and the inability to care for self as governed by local legal statute. ‚  
Nursing
Monitor for safety concerns and establish a safe and supportive environment. ‚  
Discharge Criteria
Based on the patient 's ability to remain safe in the community. It reflects a combination of suicide risk, level of psychotic symptoms, support systems, and the availability of appropriate outpatient services. ‚  

ONGOING CARE


FOLLOW-UP RECOMMENDATIONS


  • Long-term symptom management and rehabilitation depend on engagement in ongoing pharmacologic and psychosocial treatment.
  • Monitoring is based on evaluation of symptoms (including safety and psychotic symptoms), looking for the emergence of comorbidities, medication side effects, and prevention of complications.

DIET


  • Newer atypical antipsychotics confer a higher risk of metabolic side effects such as diabetes, hypercholesterolemia, and weight gain.
  • Although there are no specific dietary requirements, attention should be paid to the high risk of development of obesity and metabolic syndrome in individuals with schizophrenia.

PATIENT EDUCATION


  • National Institute of Mental Health: Schizophrenia, at www.nimh.nih.gov/health/topics/schizophrenia/index.shtml
  • Helping a Family Member with Schizophrenia: www.aafp.org/afp/20070615/1830ph.html
  • National Alliance on Mental Illness (NAMI): www.NAMI.org

PROGNOSIS


  • Typical course is one of remissions and exacerbations. Although uncommon, there are known cases of complete remission and of refractory illness
  • Negative symptoms are often most difficult to treat.
  • Excessive mortality occurs due to suicide, accidents, coronary artery disease, pulmonary disease, or substance use disorders; guarded prognosis

COMPLICATIONS


  • Side effects from antipsychotic medications including tardive dyskinesia, orthostatic hypotension, QTc prolongation, and metabolic syndrome
  • Self-inflicted trauma and suicide
  • Combative behavior toward others
  • Comorbid addictions, including nicotine (13)[A]

REFERENCES


11 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association;2013.22 McGrath ‚  JJ. Variations in the incidence of schizophrenia: data versus dogma. Schizophr Bull.  2006;32(1):195 " “197.33 Riecher-R ƒ Άssler ‚  A, H ƒ €fner ‚  H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl.  2000;102(407):58 " “62.44 Laruelle ‚  M, Kegeles ‚  LS, Abi-Dargham ‚  A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci.  2003;1003:138 " “158.55 Norman ‚  RM, Manchanda ‚  R, Malla ‚  AK, et al. The significance of family history in first-episode schizophrenia spectrum disorder. J Nerv Ment Dis.  2007;195(10):846 " “852.66 Fagerstr ƒ Άm ‚  K, Aubin ‚  HJ. Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin.  2009;25(2):511 " “518.77 Hasan ‚  A, Falkai ‚  P, Wobrock ‚  T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry.  2012;13(5):318 " “378.88 Shenton ‚  ME, Dickey ‚  CC, Frumin ‚  M, et al. A review of MRI findings in schizophrenia. Schizophr Res.  2001;49(1 " “2):1 " “52.99 Essali ‚  A, Al-Haj Haasan ‚  N, Li ‚  C, et al. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev.  2009;(1):CD000059.1010 Mizuno ‚  Y, Suzuki ‚  T, Nakagawa ‚  A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull.  2014;40(6):1385 " “1403.1111 Mojtabai ‚  R, Nicholson ‚  RA, Carpenter ‚  BN. Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Schizophr Bull.  1998;24(4):569 " “587.1212 Grant ‚  PM, Huh ‚  GA, Perivoliotis ‚  D, et al. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry.  2012;69(2):121 " “127.1313 Saha ‚  S, Chant ‚  D, McGrath ‚  J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry.  2007;64(10):1123 " “1131.

ADDITIONAL READING


Saks ‚  E. The Center Cannot Hold: My Journey Through Madness. New York, NY: Hyperion; 2007. ‚  

SEE ALSO


Algorithm: Delirium ‚  

CODES


ICD10


  • F20.9 Schizophrenia, unspecified
  • F20.0 Paranoid schizophrenia
  • F20.1 Disorganized schizophrenia
  • F20.2 Catatonic schizophrenia
  • F20.5 Residual schizophrenia
  • F20.3 Undifferentiated schizophrenia
  • F20.81 Schizophreniform disorder
  • F20.89 Other schizophrenia

ICD9


  • 295.90 Unspecified schizophrenia, unspecified
  • 295.30 Paranoid type schizophrenia, unspecified
  • 295.10 Disorganized type schizophrenia, unspecified
  • 295.20 Catatonic type schizophrenia, unspecified
  • 295.40 Schizophreniform disorder, unspecified
  • 295.80 Other specified types of schizophrenia, unspecified
  • 295.60 Schizophrenic disorders, residual type, unspecified
  • 295.70 Schizoaffective disorder, unspecified
  • 295.50 Latent schizophrenia, unspecified
  • 295.00 Simple type schizophrenia, unspecified

SNOMED


  • 58214004 Schizophrenia (disorder)
  • 64905009 Paranoid schizophrenia (disorder)
  • 35252006 Disorganized schizophrenia (disorder)
  • 191542003 Catatonic schizophrenia (disorder)
  • 26025008 Residual schizophrenia (disorder)

CLINICAL PEARLS


  • A debilitating chronic mental illness that affects all cultures
  • Schizophrenia is characterized by positive symptoms, including hallucinations such as voices that converse with/about the patient, delusions that are often paranoid, and negative symptoms, including flattened affect, loss of a sense of pleasure, loss of will/drive, and social withdrawal.
  • Multidisciplinary teams to enhance patient and family coping with serious and persistent mental illness, to prevent and treat comorbidities, and to promote recovery
Copyright © 2016 - 2017
Doctor123.org | Disclaimer